A novel live-attenuated vaccine candidate for mayaro Fever.
PLoS Negl Trop Dis
; 8(8): e2969, 2014 Aug.
Article
en En
| MEDLINE
| ID: mdl-25101995
ABSTRACT
Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
3_ND
Problema de salud:
3_dengue
Asunto principal:
Vacunas Virales
/
Alphavirus
Límite:
Animals
País/Región como asunto:
America do sul
Idioma:
En
Revista:
PLoS Negl Trop Dis
Asunto de la revista:
MEDICINA TROPICAL
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos